Ophthalmology 360
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Photo Contest
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
2nd Annual Photo Contest - Enter Here!
Ophthalmology 360
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Photo Contest
    • Industry Council
    • Advisory Board
Home > Retina > Study highlights global variations in retinoblastoma outcomes post-enucleation
  • Retina

Study highlights global variations in retinoblastoma outcomes post-enucleation

Kelsey Moroz

There are significant regional differences in the histopathological features and patient outcomes of retinoblastoma following primary enucleation, according to a study that noted, specifically, patients in Asia and South America experience a higher risk of orbital tumor recurrence, systemic metastasis, and death compared to those in Australia, Europe, and North America.

A recent retrospective study analyzed high-risk histopathological features in 1426 eyes primarily enucleated due to retinoblastoma (RB) across 5 continents.

The study found significant regional differences in histopathological characteristics and patient outcomes. The majority of cases were reported in Asia (65%), with much smaller percentages from Australia (2%), Europe (8%), North America (11%), and South America (14%). Key high-risk histopathological features, such as massive choroidal invasion and post-laminar optic nerve invasion, varied widely, with Asia and South America showing higher rates compared to other continents.

Reference
Kaliki S, Vempuluru VS, Bakal KR, et al. High-Risk Histopathological Features of Retinoblastoma following Primary Enucleation: A Global Study of 1426 Patients from 5 Continents. Retina. 2024;doi: 10.1097/IAE.0000000000004250. Epub ahead of print. PMID: 39151183.

Share

Related Content

  • Retina

Heidelberg receives FDA clearance for updated SPECTRALIS software

  • Retina

Aflibercept 8 mg demonstrates favorable safety profile in large nAMD cohort

  • Retina

Aflibercept 8 mg shows modest benefits in difficult-to-treat nAMD cases

  • Retina

AXPAXLI meets superiority endpoint in SOL-1 Phase 3 wet AMD trial

  • Diabetic Macular Edema

Hawaiian Eye Meeting update: TKI therapy may reduce treatment burden in DME and wet AMD

  • Retina

Metformin linked to lower incidence of intermediate AMD in patients with diabetes

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Ophthalmology 360

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon